

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/045877 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) *A61K 31/502* (2006.01)
C07D 411/14 (2006.01) *A61P 31/20* (2006.01)

(21) International Application Number:

PCT/GB2006/003889

(22) International Filing Date: 19 October 2006 (19.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/728,050 19 October 2005 (19.10.2005) US
0521373.1 20 October 2005 (20.10.2005) GB
60/822,663 17 August 2006 (17.08.2006) US

(71) Applicant (for all designated States except US): **KUDOS PHARMACEUTICALS LIMITED** [GB/GB]; 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JAVOID, Muhammad, Hashim** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **MENEAR, Keith, Allan** [GB/GB]; Kudos Pharmaceuticals Limited 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **GOMEZ, Sylvie** [FR/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **HUMMERSON, Marc, Geoffrey** [GB/GB]; Kudos Pharmaceuticals Limited 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **MARTIN, Niall, Morrisson, Barr** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG

(GB). **SMITH, Graeme, Cameron, Murray** [GB/GB]; Kudos Pharmaceuticals Limited 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **COCKCROFT, Xiao-Ling, Fan** [GB/GB]; 90 Rushams Road, Horsham Sussex RH12 2NZ (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES



(57) Abstract: 1.A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from formula (i), where Y^1 is selected from CH and N, Y^2 is selected from CH and N, Y^3 is selected from CH, CF and N; and formulae (ii), (A) and (B) where Q is O or S; R^D is formula (C) wherein R^{N1} is selected from H and optionally substituted C_{1-10} alkyl; X is selected from a single bond, NR^{N2} , $CR^{C3}R^{C4}$ and $C=O$; R^{N2} is selected from H and optionally substituted C_{1-10} alkyl; R^{C3} and R^{C4} are independently selected from H, R, $C(=O)OR$, where R is optionally substituted C_{1-10} alkyl, optionally substituted C_{5-20} aryl or optionally substituted C_{3-20} heterocyclyl; Y is selected from NR^{N3} and $CR^{C1}R^{C2}$; R^{C1} and R^{C2} are independently selected from H, R, $C(=O)OR$, where R is optionally substituted C_{1-10} alkyl, optionally substituted C_{5-20} aryl or optionally substituted C_{3-20} heterocyclyl; R^{C1} and R^{C2} together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C_{5-7} carbocyclic or heterocyclic ring; and when X is a single bond R^{N1} and R^{C2} may together with the N and C atoms to which they are bound, form an optionally substituted C_{5-7} heterocyclic ring; and when X is $CR^{C3}R^{C4}$ and R^{C4} may together form an additional bond, such that there is a double bond between the atoms substituted by R^{C1} and R^{C3} .

WO 2007/045877 A1